Nosebleed breakthrough? new block may beat painful packing
NCT ID NCT07421622
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study will compare two methods for stopping nosebleeds in 40 adults: standard nasal packing and a greater palatine foramen block (an injection of numbing medicine). The main goal is to see which causes less pain and which controls bleeding better. Results will be measured 24 hours after treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- 2% lidocaine with adrenaline (local anesthetic)
- What this could lead to
- If GPFB works better, it could offer a less painful way to stop nosebleeds in the emergency room.
- What could go wrong
- This is a very small pilot study (40 people) that hasn't started yet. The block may not control bleeding as well as packing, and there are risks like allergic reaction or nerve injury.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Presentation with active anterior epistaxis * Failure of initial conservative measures (e.g., nasal compression and topical vasoconstrictors) * Ability to provide informed consent and those who consent for the study. Exclusion Criteria: * Suspected or confirmed posterior epistaxis * Known bleeding disorders or platelet count \<50,000/mm³ * Use of anticoagulants with supratherapeutic INR * Known allergy to local anaesthetic agents
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Epistaxis nosebleed are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.